A large stake of my portfolio is now with this share, so much as...

A large stake of my portfolio is now with this share, so much as I'd like to buy more (I think its at its best value ever) I will try to hold off. I still really like its prospects as molecular methods are replacing many traditional methods in diagnostic medicine at present. Its just a matter of how well the GSS method will compete with other products available. I think it will as it has distinct advantages (3base technology allows for great mulitplexing), but one never knows. Its hard to tell what sales they are achieving in Europe so far - it would be nice to have more info on this, but then they have only recently got EU approval for enteric test so maybe this is yet to come. Through experience I have learnt to multiply by 3 the time frame one expects for biotechs like this to achieve their goals, but that its worth waiting. As Bioshares mentioned a couple of weeks ago that the FDA process next year is the next major driver of its value, although I'm hoping we'll see continued steady increase in sales before then. My understanding is they've already started the trials for FDA.